(BioRxiv All) Serum proteomics reveals distinct phenotypic signatures to IL-6 blockade between two immunotherapies: A recent clinical study tested the effects of two different monoclonal antibodies (mAbs) (siltuximab, anti-IL6; tocilizumab, anti-IL6R) on the fate and function… #BioRxiv #MassSpecRSS
Posts by Catherine Sniezek
3 weeks ago
7
4
0
0
I had Google overview cite the UWPR that CHAPS and SDS were mass-spec compatible. For the record, UWPR’s cited document reports otherwise.
7 months ago
2
0
0
0